Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Issue 10 (7th March 2017)

• Record Type: Journal Article
• Authors: Balasubramanian, Preetha; Kumar, Rajnish; Williams, Constance; Itri, Vincenza; Wang, Shixia; Lu, Shan; Hessell, Ann J.; Haigwood, Nancy L.; Sinangil, Faruk; Higgins, Keith W.; Liu, Lily; Li,, Liuzhe; Nyambi, Phillipe; Gorny, Miroslaw K.; Totrov, Maxim; Nadas, Arthur; Kong, Xiang-Peng; Zolla-Pazner, Susan; Hioe, Catarina E.
• Is Part Of: Vaccine. Volume 35:Issue 10(2017)
• Page Start: 1464
• Page End: 1473
• Publication Date: 2017-03-07
• Subjects: HIV -- HIV envelope -- V3 -- Mimotopes -- Antibodies; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.11.107
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Abs with distinct V3-binding modes (cradle and ladle) are made during HIV infection. In contrast, HIV envelope vaccines induce either the cradle- or the ladle-type Abs. The types of V3 Abs elicited differ depending on the vaccinated animal species. V3 cradle- and V3 ladle-type Abs induced by vaccination can neutralize virus. Abstract: The V3 loop in the HIV envelope gp120 is one of the immunogenic sites targeted by Abs. The V3 crown in particular has conserved structural elements recognized by cross-reactive neutralizing Abs, indicating its potential contribution in protection against HIV. Crystallographic analyses of anti-V3 crown mAbs in complex with the V3 peptides have revealed that these mAbs recognize the conserved sites on the V3 crown via two distinct strategies: a cradle-binding mode (V3C) and a ladle-binding (V3L) mode. However, almost all of the anti-V3 crown mAbs studied in the past were isolated from chronically HIV-infected individuals. The extents to which the two types of anti-V3 crown Abs are generated by vaccination are unknown. This study analyzed the prevalence of V3C-type and V3L-type Ab responses in HIV-infected individuals and in HIV envelope-immunized humans and animals using peptide mimotopes that distinguish the two Ab types. The results show that both V3L-type and V3C-type Abs were generated by the vast majority of chronically HIV-infected humans, although the V3L-type were more prevalent. In contrast, only one of the two V3 Ab types was elicited in vaccinated humans or animal models, irrespective of HIV-1 envelope clades, envelope constructs (oligomeric or monomeric), and protocols (DNA plus protein or protein alone) used for vaccinations. The V3C-type Abs were produced by vaccinated humans, macaques, and rabbits, whereas the V3L-type Abs were made by mice. The V3C-type and V3L-type Abs generated by the vaccinations were able to mediate virus neutralization. These data indicate the restricted repertoires and the species-specific differences in the functional V3-specific Ab responses induced by the HIV envelope vaccines. The study implies the need for improving immunogen designs and vaccination strategies to broaden the diversity of Abs in order to target the different conserved epitopes in the V3 loop and, by extension, in the entire HIV envelope.